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Abstract
Bacterial resistance to many of the modern antibiotics is a major healthcare issue.
With the advent of genomic sequencing projects, there is the potential to define all
bacterial genes that are essential for viability in the clinically relevant bacteria such as
Streptococcus-pneumoniae-and-Staphy[ococcus-aureus;-'P here-are-potentially-uE:~I>lo!ted-----,------,--1
targets for antimicrobial agents in the pool of essential proteins-that will lead to the
I
- discovery of new antibiotic cheniical entities. The CCA-adding enzyme is an important
component in protein synthesis because it add~. the universal and essential 3' sequence of .\
-C-C-A totRNA molecules. The CCA~adding enzyme is not the t(JIget of any current
antibiotics. Based on'-homology to the Bacillus subtilis papS gene, the eea gene of S.
pneumoniae was predicted to be a nucleotidyltnmsferase. The S. pneumoniae Cca protein
has been overe~pressed, purified, and characterized. It is a CCA.:adding enzyme.
1
Introdudion
A. Why search for novel antimicrobial targets?
One ofthe greatest challenges within the!TIedical community today is. the
managementof bacterial infections (Anderson 1999). Many'of the clinically relevant
pathogenic bacteria have become resistant to multiple antibiotics.. Although there are
numerous antibiotics ~urr~nt1y available, they work by targeting a relatively small
number of pathways withjn the bacteria such as cell wall biosynthesis, DNA replication,
and prot~insynthesis. Efforts to improve the current antibiotics have focused on
chemical modific~tion of current drugs, but this approach is being compromised as
bacteria become resistant to second, third, and fourth generation drugs. This crisis can be
illustrated by the emergence of E. coli, K. pneumoniae, and Salmonella strains that are .
. .. resistant to the third generation cephalosporins, cefoperazone and ceftriaxone (Murray
1989)..
Streptococcus pneumoniae is the primary pathogen responsible for community-
~~~~~_._--- --~ ..---
------~-- ,---acquired pneumonia in the elderly and bacterial meningitis in young children (Hamson
1998). Themanagement of this pathogen has been complicated by the emergence of
strains resistant to penicillins, cephalosporins, erythromycin, and other macrolides
(Brown et al1998, Heffelfinger et 0,12000). Even mor~worrisome is report of
l .
Streptococcus pneuinoniae strains that are tolerant to vancomycin, an antibiotic that is
. r .
considered the last line of defense in the physician's arsenal (Novak et a12000).
Vancomycin interferes with cell wall synthesis in bacteria(Physiciqn's Desk Reference
. 2000). ~t is important~ note that everi this new antiQioticdoes not inhibit a. novel target.
2
. .,
The lack of diversity in the current targets is one reason that antibiotic-resi.stant
. - - -
bacteria have become a major threat to patients. It is important that the newest antibiotics
have novel targets to minimize the chance for rapid r.esistance to evolve (Holmes' et ai.
2000, Moir et al. 1999)~
--.-~---~--- ----------- ---- -_ .. _-------- -------._-.---_.._.~~~-~~~--~~--=-::---=-=
r
B. How does one fmd a new antibiotic?
The tniditional method of identifying antimicrobial ~gents involves sereening
. .
chemicals for those that inhibit bacterial growth and then trying to ascertain t4e cellular
" -
target and ultimately, the mode of action. However, the advent of genomic sequencing
projects has changed the way many rese£ch groups approach the discovery of
..
antimicrobial agents. The genomic sequence data derived from clinically important
bacteria offers researchers the ability to perform a systematic and global analysis of .
genes. Specifically, genes that may be essential to the organism's viability can be
. identified by inactivating the gene via plasmid insertion mutagenesis (Apfel et ai1999)
or allelic replacement in wIVch a portion of the gene is deleted and a resistance marker is
(
inserted (Norgren et ai1989, Buckley et al1995, O'Connell et ai1993). These so-called
knockout studi~s do not prove essenti~ity, but these experiments are useful in
eliminating further efforts on 'genes which are not essential for in vitro growth.
Obviously, a valId target has to be essential to bacterial viability in an infective state..
. Once_a.I1~s~ential ge,l1f~ isjdeQtif!~!.a biochemical assay-can_be.developed.for-high-.
throughput screening of synthetic compounds or natural products to identify those that
inhibit the essential pr~tein'~ activity (Holmes et ai. 2000). in essen~e, the l1eW:appr~ach
---_.. -_._~-_ .. " ..--~-~~:--_.'-
3
'-' .
~antibiotic discovery is the reverse~Of the traditionai methods because the target of an
~ . .
,~- -,,: ';' '~-') ~"'\--'-', -·inhibito.I::i~Mre.~~}',1p!9;~~~ ..__ , _
:.;~:.'l..'l;l:~_"'",,~;,.:o:~l::I..I~~\.-,--.
An additional advantage to possessing '~;~:n~;~-;;~~'en=~~is"th~t=the'~spectfOrn-''''~'-'-'~ ,,,_ '''''=;''.~
· of a target can be determined before an inhibitor is identified. It is conceivable that a
compound could be found to inhibit growth of Gram positive but not Gram negative
bacteria. This might be because the target protein is onlyToundin Gram positives .or
-~ - "- -~....._--.~ -
. .
· because the compound cannot penetrate the Gram negative bacterial.ceIl·wall and reach .
.
the target protein. The latter phenomenon is exemplified by linezolid, a protein synthesis
inhibitor and a currently available antibiotic: Linezolid kills Gram positive bacteria
effectively, but it has lower'activity against Gram negativ~ bacteria (Eustice et al1988).
The lower potency is believed to be due to lower penneability of the Gram negative
bacteria to linezolid. The compound is active when tested against the cell-free E. coli
protein synthesis components in vitro (Shinabarger et al1997). In the genomic era,
determination of the target spectrum can be made, using bioinformatics, before a single
~. ~--------"--:o--~~ ,--~~--
experiment is performed. It would be very advantageousIor a new'antibiotictochave a
target that.is present ina broad spectrum of bacteria as well as being novel.
Alternatively, a target gene can b~(?lle that is 'present in the major bacteria that infect the
respiratory tract (S. pneumoniae, M. catarrhalis, H. influenzae), but perhaps not present
· in other clinical pathogens such as Chlamydia.
. The use of genomic comparisons among relevant organisms can establish the
,
. I
spectrum and predict how similar the protein of ihterest is among the organisms.' In many
"_ • I
cases, the essentiality of a gene to a particular pathogenic bacterium may be known, but
4
.........
not its function. Genomic comparisons can be done to predict the function of a gene of
,
<, •
interest, though nq~always accurately. Furthermore, using the information from human
it can sometimes' be determined whether the bacterial protein of interest cO!-lld be related
. )
to a human homologue~ The latter information is important for determining the extent to
which-a chemical can'be selective-in-affecting theViabilify-oftliebaetena andriof-
inhibiting human cellular functions.
_C. Why focus ona tRNA nucleotidyltransfel;"ase?
In the quest to identify novel targets using genomic sequencing data, it has
become evident that some of the potential targets are unexploited components of
pathways that are well understood. The development of high throughput assays for these
targ~ts may be less problematic when'the pathway is well studied. Translation of
messenger RNA to yield proteins has been extensively studied in bacteria (Shine and
-Dalgarno-1-9'74,-Kerppola-and-Kane-1-991,-Noller-1-993,Saks-et-a1-1;-994).--Many-of-the.~-
key components in the pathway have been identified. Messenger RNA (mRNA),
. transcribed from DNA by RNA polymerase, serves as the template for protein 'synthesis.
The encoded amino acids are brought to the ribosome attached to transfer RNA (tRNA).
The ribosome itself is made up of RNA (rRNA) and protein. Protein synthesis can be
- divided into three stages: initiation, elongation,.and termination. In bacteria, initiation
begins with the 30S ri>~osoniaJ.su1:~iiiiitsbinding to mRNA by base-p~r interacp.ons
between rRNA and the Shine-Dalgarno sequence, a sequen,ce complementary to the 3'
5
/
-,
......; .
end of 168 rRNA usually found five to ten bases upstream of the start codon. When N-
formylmethionyl-tRNA (tMet-tRNAf) binds to ffiestart codon found onthe mRNA, tJIe
large ribosomal subunit is recruited to the mRNA and tMet-tRNAf by initiation fact~rs.
This arrangement places the tMet-tRNAf in the peptidyl-tRNA site (P site) of the
ribosome. The next encoded aminoacyl-tRNA binds to th~ mRNA and ribosome in ~be
aminoacyl-tRNA site (A site) in an active process involving the elongationJactor, EF-Tu .
and hydrolysis of GTP. Elongation occurs when a peptide bond between the two amino
acids is catalyzed by the peptidyl transferase activity of the ribosome. The tMet is
transferred following peptide bond formation on to the aa-tRNA in the A site,
establishing a dipeptide. A translocation event moves the tRNAfmet from the P site to the
"exit site" (E site), and the peptidyl-tRNA moves to the P site (energetically-driven by the
. hydrolysis of GTP and involving the elongation factor G), vacating the A site.
Elongation continues as the next encoded aa-tRNA molecules enters the A site and the .
cycle is repeated until the protein is complete. Termination of protein synthesis takes
~_~place when the ribosome reaches_one_otthree-stop-codons.~Release-factors-associate-witlf--- ---:--
the ribosome in the A site, and the peptidyl transferase activity links the polypeptide to
H20 instead of an aa-tRNA. Consequently, the polypeptide is released, and the ribosome
dissociates from the mRNA. The whole process is further dependent on many auxiliary
factors.
Transfer RNA is a central component of protein synthesis. It has been referred to
as the "adapter molecule" because it connects the genetic infomiation via mRNA to the
... -- ".
protei~s~qu~nce(fr~mHoagland, 1960).. While the different tl\Nf m~~ulesvary in
. 6 ...
---------~--
__ size JGO tg 95 ba§~§),Jh~y dQ~h-~~ a siI!J.ilar two dimensional cloverleaf structure
';:....';;':;:::::h~::'~:-::::~-.~.·_::~:.:::c""";"-=-_:;'c.::·~-.-~~~ ..:--~ :'~::::::':..·,:":~::.·.:::,:,;,~_::,;::-::.:'_7::'-:-} ....:-:.":;;.::;~_:;.:.":-':'_::~::",;:--:':C;'::-.--':;:".'7.:-.::.-;:"_'::..:':;- ... ;'.:~'::.-::;:':':::,~~~:o':.-.~,":;:::':':::.~.:':'.:_:;:::::_~ ....::7":'_~~~;~;,-.:.;"~"-.~~.;;;,:~~~;,<.;~-:;--.;;;.;.;:.;::.~:.;:;: :J;_::':";_~:~;;:-;'-~;;;:-::'\~'::'ci":_:':':;~~'.':r:,~ .•; ':'c:~:;_Ii'~~~"\"'J:.l~J,~~;.':'_-::::"~:'::_":-::=:~
(Figure 1) and many conserved regions. Also, the tRNA molecules contain atypical base
modifications which are highly conserved. The unique structures and composition of the
tRNA molecule allow for the enzymatic attachment of a cognate amino acid as well as
distinctive interactions with the ribosome and mRNA, such as base pairing of the
anticodon-loop with-a codon sequence on the mRNA.
One of the most conserved features of the tRNA molecules is the presence of the
trinucleotide sequence -CCA at the 3' end. The cognate amino acid is linked to the 3'-
terminal adenosine by the aminoacyl-tRNA synthetase. This CCA signal emerges at the
,
3' end of the tRNA molecule as a result of the tRNA maturation process. In the
prokaryotes, many tRNA genes are polycistronically linked. After transcription, linked )
precursor tRNAsare cleaved and a 3' trailer sequence is removed via several different
ribonucleases including RNase D .and RNase T(King et alI986). For tRN'A molecules
in E. coli, this processing exposes the CCA sequence, About 24% of the tRNA genes in
-~acillus siiotilirdo-not have-theeCA-s.equence-encoded(Vold-1985}; -The- ,.. - '-
archaebacteria have tRNA genes with and without the CCA sequence encoded (VoId
1985). When the CCA sequence is absent, the sequence must be enzymatically added via
ATP(CTl;'):tRNA nucleotidyltransferase (CCA-adding enzyme) after tlle cleavage ofthe
J'
3' trailer sequence. Lastly, a 5' leader sequence is removed by RNase P and several post-
..
transcriptional base modifications occur to complete the tRNA ma!uration process.
·Interestingly, E. coli has a CCA-adding enzyme, ~hich is not essential for cell
. - ~~
viability, although its 'absence results iii slow growth (Zhu and De~tscherA~1' It may
7
/A Invariant
----- --~~--~_._- --'--~_.---_._--
o Semi-invariant
e Any base
e Sometimes absent
*. modified blises
Nucleotide 73
Variable loop
~
.,
Figure 1: tRNA 2D cloverleaf structure (from Lewin 1997). Used by permission
from Oxford University Press. '
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Figure I: tRNA 2D cloverleaf structure (from Lewin 1997). Lised by pennission
from Oxford Univcr~ity Press.
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appear surprising that E. coli, in which all tRNA genes encode the CCA sequence, has a
CCA..,adding enzyme, but the role of the enzyme is to repair damaged 3' ends of tRNA in
, -'-"':::'.'·'~·'1~_.•
....-.', ·- ... ··~'··",.,",·<- ....... _A'
'~" ...~~"cO.'.'11UJ,;...._';:.J.:~~~::.::.;.:~:.::::.::::.::::.:=~=~-=..::.-.._ ----.--::.~-~-~::~,-.:;:._._~:7::::.:.::::::_::=.::_::=_.:-.:.'''""7 :-:,,:,,~"'-::;:''.:::-i:::;::'~:':::=:~''::::::-~':.:,:::: ..=~,;::=::::-:--::,' .. '--:-' .:-~::.:-.;:::::::::::::_-.:::-.:::,"::,:~=::
E. cO,li (Reuven et al1997). Identification of a putative tRNA nucleotldyltransferase In ".
, Streptococcus pneumoniae was made by searching a genomic sequence database with the
Bacillus subtilis PapS protein., Recently, the B. subtilis papS gene was in fact shown to
encode forCCA..adding enzyme activity (Raynal etal 1998). A phylogeneticanalysis-of.-
the CCA-adding enzyme identified possible CCA-ad,ding enzymes in otherpathogenic
,
bacteria (Figure 2). The most significant homology identified in a BLAST search against
the public datab,ases with the S. pneumoniae Cca protein was the B. subtilis PapS protein.
The presence of the CCA-adding enzyme in a broad spectrum of bacteria and the
j'\
requirement of the CCA signal for protein synthesis makes the tRNA
nucleotidyltransferase an attractive protein to investigate as a potential antimicrobial
target.
, ,
'D:-What-do-we 'know'abollt-the-necessity'of-the CCA-signal,for·protein ·synthesis?
An amino acid is attached to its corresponding tRNA by the cognate aminoacyl-
, ,
tRNA synthetase priorto any interaction with the protein synthesis machinery. In
general, there is a specific aminoacyl-tRNA synthetase for each amino acid. The
degeneracy of the genetic code means there is more than one possible codon.for & given
, .
amino acid and thus, more than one tRNA to which the amino acid can be attached.'
Despite this degenera~y, it is clear that the anticodon nucleotides are important for the
. '
, ~
recognition of a tRNA by a specific aminoacyl-tRNA synthetase (Schulman and Pelka
9
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. Proteus mira 1
62 Vibrio cholerae 1
78 Haemophilus influenzae 1
Pseudomonas aeruginosa 1
Pseudomonas putida
Neisseria gonorrhoeae 1
'----......'"'1 Neisseria meningltldls 1_
-~--_.~ .•. , Moraxella catarrhalis"'"
. !ih
10 Chlamydia trachomatis 1'----~9 , Chlamydia pneumoniae 1
'------------ TreponerTla pallidum 2
'----------Chlamyaia trachomatis2--
:31---' Staphylococcus epidermidis., 1
Staphylococcus aureus 1
Staphylococcus haemolyticus 1
Streptococcus pneumoniae 1
Streptococcus pyogenes 1
Enterococcus faecalis 1
'---~-- Bacillus subtilis 1 eeA
r---......-.tmC==-~ Homo sapiens
.-----"'1 Caenorhabditis elegans 1 IMetazoans
L..._,...- Rickettsia prowazekil1
.....------ Borrelia burgdorferi 1
.......-------- Helicobacterpylori 1
.....--------- Treponema pallidum 1
,.....;--- Saccharomyces cerevislae 1
'----- Candida alblcans 1
L... White lupine
L... Aspergillus fumlgatus 1
'-------- Schlzosaccharomyces pombe 1
'------------.--,-- Synechocystls sp 1
L 1!!0~0t:==~;;: Mycobacterium tuberculosis 1
Streptomyces coelicolor 1
9 Yerslnia pestis 2
Proteus mlrabilis 2
Escherichia coli 2 CC'A'
r---- Actinobacillus actinomycetenfCbmitans'1-- --- - .---- --
Haemophilus influenzae 2
,----' Vibrio. cholerae 2
Neisseria gonorrhoeae 2,.::.::.r--...:.::~ Neisseria meningltidis 2
r--------:..:.::t Pseudomonas aeruginosa 2
'----,...-- Moraxella catarrhalls 2
. Bacteroides fragilis 1
Prevotella ruminicola 1
.....--- Porphyromonas gingivalis 1
"'~
'-------- Chlorobium tepidum 1
50
0.1
'----------...;...--------- Aqulfe:x aeolicus 1
Figure 2: Phylogenetic analysis of poly(A) polymerase I (PAP) and'
tRNA CCA-adding enzYme~. Analysis by Jam~~, R. Brown at
SmithKline Beecham, 1999.
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1988, Pallanck et alI995). However, the synthetase also recognizes other sequence-
specific or structurally-specific features of the tRNA molecule. At the 3' end of the
tRNA lies the single-stranded CCA sequence. Its exposure facilitates the ability for an
aminoacyl-tRNA synthetase to link an amino acid to the 3'-terminal adenosine, forming,,-
an ester bond. In addition to the anticodon, the acceptor stem region, adjacent to the 3'
,...
end of the tRNA, and nucleotide 73, a variable nucleotide that precedes t~e CCA
sequence, playa role in placing the 3'-terminal adenosine of the tRNA molecule within
the active site of the appropriate synthetase for aminoacylation (Schulman and Chambers
1968, Schulman 1972, McClain and Foss 1988, Hou and Schimme11988). When the 3'-
terminal a~enosine is modified or removed, aminoacylation is inhibited (Roy and Tener
1967). Interestingly, '!ifferent modes of inhibition were observed depending on the
. modification. It·was suggested from the work with 3'-modified tRNAs that the 3'-
. .
terminal A acts as a enzyme effector, causing a conformational change in the synthetase
which leads to a tighter interaction between the synthetase and the tRNA (Von der Haar
____________and_Gaertner_l-9'74). --'I'herefore,the-3'-tenninal-A-is-notiusta-passive-a~ceptor.-. - ... -------.--
Additional work with the 3'-modified tRNA molecules showed either of the two terminal
hydroxyl groups can be esterified; the preferred group is characteri&tic.of a particular
tRNA synthetase (Spintzl and Cramer 1979).
In addition to being the attachment point between the amino acid and tRNA, the
CCA sequence is believed to have an important role in how the tRNA molecule interact;)
with the other components of the proteiii"synthesls machinery--:-Theanunoacyl=tRN:A-is
brought to the ribosome via a ternary complex consisting of the aminoacyl-tRNA, .
11
___ --- , t?!.2!l:g~!!onJactorEP.:Tu, and GTp_. The CCA sequ~Q:ce does not appear to be di,rectly
~:"-'-- -..,:,'..,~~. ";':I.i.":c...'~ ;'; ,; ~;:.;:'~ ~;'.-.:.:,:,,-:~~,). t:;,,'.:;',:; ~:- ,';,- ~:;-. :;;,:;,:;;,:,-,'';;':'':.',;"',;,.,'; .: ::,,:';';;;;-•.;; :;;/;";,~7: ,';;';.;;';;;;.;:i.i....7.C;,--;:;:,-:-:~:;:;:::::;::::;:.::.: ;':';;::,.~::: .~; ':::_:':;;"~; ,:' : :,,;;.~, :,:;c~.:;'_"::,:,;.'·_.~.:"';,:·. _":.:;::;';-';~:'~ ;;":.\,_ :;:-'-"l:;k:'';i" i:; .:-:: :.:,~ ~~ ~;.'_ '.~ ::.~~. ~." : ... , :'-:,' .:::::~:.:",'- ~::":- \,~ >::;" ,,:: !'t.'.:~~:::-~ '~:'.-:.:;~ ::_:;~:~~:;~ . '.' .'.,. ,--;. ',::;-;- :.;"_~).::.~_' '_', _ "'_"-"~¢';"_ ,,~io
•invo~ved iii the ternary complex, but may remain exposed for interactions once the
.,ft
aminoacyl-tRNA reaches the ribosome (Kruse et al. 1980, Ott et aI1989). There are at
least three sites on the ribosome where the aminoacyl-tRNA can interact: the A site, P ,
site, and E site. When the ternary complex reaches the A site of rhe ribosome, there
appears to bean intetactionbetweentheCGAsequenceand theA siteb_ased_on~tydles.
using 2'(3')-O-(aminoacyl) oligonucleotides with different terminal nucleotide sequences
(Tezuka and Chladek 1990). The mutant tRNA molecules with alternative bases for the
adenosine or first cytidine were the poorest substrates for peptidyltransferase activity,
indicating that these sequences are involved in essential interactions with the ribosome,
. ,
although there is no evidence for Watson-Crick base pairing between the CCA sequence
and rRNA at the A site (Tezuka and Chladek 1990). On the other hand, nucleic acid-
protein interactions have not been ruled out.
During the elongation step of translation, a peptide bond is formed between the
-------
amino acid attached to the tRNA in the A site'and the C-terminal amino acid of the
growing polypeptide attached to the tRNA in the!> site. When this happens, the peptide
is transferred onto the tRNA in the A site. A translocation event must occur to transfer
the peptidyl-tRNA into the'P site, vacating the A site. Simultaneously, the de-
.aminoacylated tRNA moves from the P site into the E site. Many research groups have
fQundJhatthe CCA signal is very important in_these events (Monro et a11968, Lill et al
198?, Moazed and Noller 1991, Tamura 1994). For example, Robin Monro and
colleagues were able to focus on the formation of the peptide bond by utilizing small
12 .
molecules that interacted with the 50S ribosomal unit in the same manner as aminoacyl",
r • • _
tRNAs and tRNAmolecules attached to a growing peptide. The aminoacyl-tRNA was
replaced by puromycin and the peptidyl-tRNA was replaced by small oligonucleotides
attached to formyl-methionine: Using this "fragment reaction," the researchers found that
~----/
the entire CCA sequence was needed for the peptidyltransferase reaction. More recent
mutagenesis and footprinting studies have shown that the CCA sequence on the tRNA
interacts through base pairing with the 23S rRNA in the P site to facilitate the formation
of the peptide bond (Tamura 1994). Using mutant tRNAphe, translocation of the de-
aminoacylated tRNA from the P site to the E site has been shown to involve the teiminal
adenosine binding to a portion of the 23S rRNA in the E site along with the tRNAlEF-G
.t • .. . "\'
:1
interactions (Lill et al 1989).
Much of the research regarding the 3' end of the tRNA molecule has been
perfonp.ed using E. coli anq yeast compop.ents, aJ1ditseemsreasQnablethatthe
paradigms established for these systems will extend to other bacteria. Nevertheless, it is
. possible tliatllle interactiorisof the C(;A signal with the protein synthesis coml'0nents ate
not completely elucidated. However, it is clear that without exception, the CCA
sequence is present on all mature tRNAs and that the presence of this sequence is
. essential to the processes of protein synthesis.
E. What do we know about tRNA nucleotidyltransferase?
The CCA-adding enzyme is a memberof the nucleotidyltransferase family. Other
,members of the nucleotidyltransferase family include poly(A) polymerase and
- 13
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Figure 3 (from Martin and Keller 1996): arrows depict ~ strands and cylinders
depict a helices. (A) Catalytic domains from eukayotic Cca, Pap, and DNA pol
~. (B) Catalytic dOlnains.Jrom E. coli PoIX(J\) polymerase I, B.subtilis PapS and
E. coli Cca. Helix J and ~ strands 3 and 4 were not found in the prokaryotic .
enzymes. 1,Jsed by permission from Oxford University Press.
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B
Figure 3 (from Martin and Keller 1996): arrows depict ~ strands and cylinders
depict a helices. (A) Catalytic"domains from eukayotic Cca, Pap, and DNA pol
~" (B) Catalytic domains fromE. coli poly(l'\) polymerase ~)7iti\ PapS UIld--------
E. coli Cca. Helix J and ~strands :; and 4 were not found in the prokaryotic
enzymes. Used by permission from Oxford University Press.
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\
polynucleotide phosphorylase. Members of the nucleotidyltransferase family show
.; •.'. . t. .
..~~.. !:-." . - ..~.' -
homology' at the N-terminal end over a region of 2S.kDa, including the catalytic core..
'~"'-."~;;:,,,;:,,,,~cc~:.oC,,",,,,::Withinthis_cfamiliY,Jbe,,CCA:oa..~Q.mg,-~.n~)'m~hliStb~··gre~testspecificityin· haHt"uses-">'''·_···,,··,"'''';·····_··,,''_···
only·the 3' endoftRNA as a primer. No heterogeneity has been detected in the CCA
sequence addea or in the length of the sequence despite the absence of any obvious
template (Deutscher 1982, Yue et al1996). Given the importantrolesthatthe CCA-
sequence has in tRNA interactions with the prote~n synthesis machinery, it is believed
that the activity of the CCA-adding enzyme is essential when tRNA genes do not encode
the CCA sequence.
F. Is the CCA-adding enzyme a possible antimicrobial target?
There are no known antibiotics currently available that target the CCA-adding
protein. The eea gene was shown to be essential in S. pneumoniae using the allelic
replacement method in attempts to delete the gene (D. Holmes, personal communication).
Genomic"comparisons-show~the eca-gene-tobe ·presentin.. several.pathogenicilly.releyant
.r--"
bacteria, such as H. influenzae and S. aureus (Figure 2). In a search of the public
databases,. a human homologue was not identified. However, proteins within the
nucleotidyltransferase family are also part of the X polymerase superfamily, of which -
human DNA polymerase ~ is a member (Figure 3). It appears that there' is structural
conservation of enzymes involved in polynucleotide synthesis, primarily in the active
sites (Martin and Keller 1996). There do~s appear to be a discrete and distant grouping
of the eukaryotic proteins that are rel~ted to the bacterial CCA-adding enzymes (Figure
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_:..".._"",,~y: Therefore, there isa possibility for inhibitors of bacterial CCA-adding enzymes to be
.........••A_~'......-.-.,.".;;."...."_,=.l~.H.~.)..U).;..:..;:..~;;:;:~";:,......;~ .....~~"",...-...,~••'-''''''';".;"';";·;.:;.; ..;.;.:.;,;::.;;,;:.-_: •.;,:',;..·,·,'.'~.\~;l;._ "' •••~-'.,.,;: ..~~.,~;z:::..:::::;.~~ ...~;;.;:;;.;;;~-.-~:.;~;:;.::~:...;:.:~~;;:'::". -; .. ,.".-_".-;,•.:-:::.7.:~:,~,~.·_S7:':;:;:~~;;~";}."i.;;;;:::'·,' ..·-;I";;"J-""""~';;'-";.:::~.".;:;~';';)':,:-:::-r,,::~::.-.;:Ir~~""t~";-
selective because it is unclear if an inhibitor would interact in the same way with the
bacterial and eukaryotic enzymes in vivo.
G. What is the function of Streptococcus pneumoniae Cca?
Through isolation and characterization of the encoded protein, it is the aim of this
study to understand the function of the putative cca gene identified in the S. pneumoniae
genome and its suitability as an antimicrobial target. Since the N-terminalregion,
including the catalytic domain, of proteins within the nucleotidyltransferase family is so
highly conserved, it is difficult to know for certain whether the cca gene encodes aCCA-
adding enzyme or a poly(A) polymerase based on protein sequence homologies. Here, I
report that the S. pneumoniae Cca protein is a CCA-adding enzyme.
f •
Materials and Methods
BLAST searches were done against the nonredundant public ,databases and an SB
, proprietary Staphylococcus aureus sequence database. Sequence alignment of the CCA-
, adding enzymes and the poly(A) polymerases was done using the Jotun Hein Method in
the MegAlign software (DNASl'AR) with smalLrealignments mJl,d~Il1anmllly.
~
B. Overexpression of S. pneumoniae R6 cca.
The overaIr cloning scheme is illustrated in Figure 4 , Steps 1-6.' In the initial
step, genomic DNA was isolated using a modified Maimur protocol (from J.L. Johnson
1991). The cca ORF was amplified by PCR with Pwo DNA polymerase (Boehringer
Mannheim). A rare E. coli proline codon immediately after the start codon was changed
from CCT to CCG via primer design to optimize codon usage for E. coli (Ellington and
Cherry 1997). Primers with the sequences, GATTAACqCATATGCCGTATGAAT and
GATGAATTCACTCATT'I,'TITCTCGGwere-useo to facilifate tliepre-sel1ce'ofan N- _
terminal His6. tag via pET28a; GATTAACGCATATGCCGTATGAAT and
AATCTCGAGTTTTTTCTCCCT to.utilize the C-terminal His6 tag of pET24b; and
GATTAACGCATATGCCGATGAAT and GATGAATTCACTCATTTTTTCTCCC to
yield an untagged version in pET24b.
Next, PCR products were cloned directly into pCR-Blunt (Invitrogen), digested
withthe appropriate_restrictionJ~ndonuclease (Gibco BRL) and gel purified (QIAGEN
gel purification kit). The purified fragments. (from Step 3 in Figure 4) were ligated to the
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- pCR-Blunt
---,.-.......;.' ----)
.y
Transformed E. coli with ligated
vector and performed pDNA
isolation, restriction enzyme
digestion, and gel purification of
correct fragment (cca gene)
Xho I or BeoR I .
NdeI
~}­L2J
Xho I or EcoR
...
_ =His-tag
I = T7 promoter with la~ .
operator
Transformed E. coli expression
host cells and induced Cca protein.
expression using IPTG.~
, ~
Figure 4 : Cloning scheme for the ,expression of S. pneumoniae Cc~ in. E. coli.
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Figure 4 : Cloning scheme for ,the expression of S. jJnellllloniae Cca in E. coli:
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corresponding pET vector after it was digested with the appropriate restriction
"""'" ,'", ,;;,;;cendonuclease',and,dephosphorylated(Step,4.in"FigureA)•. ,Tb.~,,£onstructs were initially
. transfonnedinto E. coli DH5a competent c~ls to circum~ent :;·::::;;~~~;;'frglifc. "~.'".
:~-_ ..._~ ..... ~';;:;
have decreased the efficiency of the transformation. Once the pET vector constructs (as
shown in Figure 4, Step 5) were verified by sequencing analysis, they were transformea' ,
~nto the E. coli expression hosts: BL21(DE3) (Strategene), BL21(DE3)/pLysS
(Stratagene), and Novablue (DE3) (Novagen). Table 1 summarizes the plasmid
constructs. Figure 5 is an plasmid map of pJA02, the plasmid used to overexpress S.
pneumoniae His6-Cca.
Table 1 : Recombinant plasmid constructs for expression of S. pneumoniae eea
Restriction
Construct Parent Hexa-Histidine sites used in Selection
Vector ta~ . clonin~ Marker .
pJAOI pET24b C-terminal Nde J/XhoI Kanamycin
~••••-._ •.. _ •• :1
-,
Resistance gene
(kanR)
pJA02
,
pET28a N-terminal NdeJ/EcoRI kanR
pJA03 pET24b none NdeJ/EcoRI kanR
~ 0
The initial induction studies were done with 3 mL cultures in LB+ ~% glucose +
50 J,LglmL kanamycin at 37°C or 18°(::: (Note, Chloramphenicol, at 35 J,Lg/mL, was added
to ~ultures with the pLy§~plasmid). Th~ cultures were induced at OD600 0.6 with 1 roM
--- --- -
" ~
,
--"-~~,-'
lPTG, unless noted, and samples were taken at three, six, or 18 hours post-inoculation.
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C. Protein Purification.
Initial sarrtjes of t,otaI,' soluble, and insoluble fractions were obtained by ..
resuspending cell·pellets in 100 jJL of 50 mM Tris pH.8.0/0.2 mM EDTA per OD6oo1
sample volume (total fraction). To obtain the soluble and insoluble fractions, lysozyme
(100 ~g/rilL) and 0.1 % (vol/vol) Triton X-lOO were added and samples were incubated
for 15 minutes at300C, then spun at high speed in a microcentrifuge for l5mirilifes. The
supernatant (soluble fraction) was placed in a fresh tube and the pellet (insoluble fraction)
was resu'spended in the initial volume of Trisl EDTA. The protein size of the His-tagged
and untagged Cca protein.was estimated via SDS-PAGE analysis using 10% Bis-Tris
NOVEX polyacylamide gel in IX SDS-MOPS buffer and Coomassie Blue stain.
For western blot analysis, the soluble fraction, column elution samples, and
control fractions were run on 10% Bis-Tris NOVEX PAGE in IX SDS-MOPS buffer and
transferred to a polyvinylidene difluoride (PVDF) membrane. The protein of interest was
probed with an alkaline phosphatase-conjugated nickel probe (Qiagen) and detected by
chemifluorescence (ECF reagent from Amersham Pharmacia Biotech). The signal was
.
visualiz~d using the Storm instrument froin Molecular Dynamics (blue fluorescence
scan).
Solubilization ofthe insoluble protein was attempted under three conditions
(Deutscher 1990, Raynal et al1998). Condition A was 20 mM Tris, lmM DTT, 100
~g/mL lysozyme, and 4 units/mL DNase (Gibco BRL), 30°C for 30 minutes. Condition
B was 10 mM glycine pH 9.4, 1 mM DTT, 10 ~g/mL lysozyme, and 4 units/mL DNase,
(J _,'
30°C for30 minutes. ·Condition C was identical to condition B with 0.8 M Nl4CI adde4.
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Figure 6 illustrates the purification scheme thatwas performed to yield purified S.
'jjneumoniae His6-Cca protein from E. coli. As shown inStep 1 of Figure 6, a 500 mL
culture, grown at 37°C was induced at OD6oo =0.6 with 1 mM IPTG. The cells were
harVested at 4 hours by centrifugation. The cell pellet was resuspended in 5 mL/ g of cell
paste in phosphate buffer + 10 mM imidazole (pH 7.5), ,disrupted by sonication and
....... fieezEltliawcyCles,' aricrcentrifugedtosepatate the soluble and insoluble fractions (Step
2, Figure 6). A His-Trap affinity chromatography column (Pharmacia) was used to
purify His-tagged S. pneumoniae R6 Cca soluble protein. The soluble fraction was
placed over an equilibrated His-Trap column (Step 3, Figure 6). Post-wash fractions
were collected from 100 mM and 500 mM imidazole elutions (pH 7.4-7.6). The fractions
tnicontained the protein of interest we~e identified via SDS-PAGE and Coomassie Blue .
staining (Step 4, Figure 6). The'fractions that did contain purified S. pneumoniae Cca
protein were desalted using Desalting size exclusion columns (Pharmacia), eluted in 10
mM Tris, pH 7.5, and quantitated using a colorometric assay from BioRad (Protein Assay
kit, standard microtiter plate format). The fractions were stored at -80°C until activity
assays were performed. Prior to performing the activity assays, the identity ofthe protein
of interest was verified by N-terminal sequencing (by Gilbert Scott, SB).
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QInsoluble fraction
~. . Resuspended in .... phosphate biffer + 10,... mM imidazole and cellswere disrupted by
sonication/freeze/thaw
cycles.PeHeted cells.500 mL fennentation:
_E. coli BL2=1=(De=E=3J)-'-/ --;---~+==~
pJA01-in LBmedia
with 50 ug/mL
kanamycin and ImM
IPTG, 37°C
Soluble fraction
placed over His-
Trap column.
. . . Gnnna
. ..~ r 500 mM imidazole elutioo
SDS-PAGEanalysisand V V V
Western Blot analysis to
determine FraCti0n.(s) :with . Assay for tRNA
His6-Cca. -----'~. nucleotidyltransferase activity and
Poly(A) polymerase activity.
Figure 6: Purification scheme of S. pneumoniae His6-Cca from E. coli over:
expression strain.
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D. Enzyme Assays .-
The tRNA nucleotidyltransferase assay (Raynal eJ al1998) and PAP assay
(Amersham product notes) were adapted to use [a,33p]ATP or [a,33p ]CTP. Specific
conditions for the tRNA nucleotidyltransferase assay were, in a20~ reaction: 50 mM
glycine pH 9.4,5 mM MgCh, 0.5 mM ATP, 150 ~g tRNA, 10 ~Ci [a,33p]ATP or
[a,33p]CTP, incubatedfo.r'10 mi1!ut~s~t37°C. Conditions for the ~~ ~~y w~r~, in a
200~L reaction: 50mM Tris Hel pH 7.9,0.25' mM NaCI, 2.5 mM MnCh, 0.2 mM ATP,
250 ~glmL tRNA, 0.5 mglmL BSA, and 20 ~Ci of [a,33p]ATP or [a,33p]CTP, incubated
for 10 ~nutes at 37°C. 'Samples were subjected to electrophoresis through a 6%
denaturing polyacylamide gel (NOVEX) and transferred to a PVDF membrane. The,
membrane was exposed to a phosphoimage screen (1 hour) and the resulting signal was
visualized using the Storm instrument.
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Results
. .A. Gene identification.
"Through gene comparisons,·a pumber of organisms were found to have deduced
.J
proteins homologous to S. pneumoniae Cca (Figure 2). For some of the bacteria, two
homologous proteins were identified. "For these organisms, it was possible to identify one
homologue as a CCA·adding enzyme and the other as a poly(A) P9lYlIl~rase by
comparison with the E. coli poly(A) polymerase and CCA-adding enzyme. The
eukaryotic proteins that were found to be similar to S. pneumoniae Cca appear to be in a
-
distinct group from the bacterial proteins. A human homologue for Cca has not been
identified and the homology shown here is based on similarity to a member of the X
polymerase family, DNA polymerase~. A homologue for Cca was found in C. elegans
(48% percent homology in conserved N-terminal domain).
Proteins that were found to be s~milar to S. pneumoniae Cca in known pathogenic
(H. influenzae) or well characterized (E. coli) bacteria were chosen for more detailed
sequence analysis. There is strong homology between the inferred S. pneumoniae Cca
amino acid sequence and bacterial poly(A) polymerases as well as the CCA-adding
enzymes (Figure 7). Characteristic of the nm::leotidyltransferase famlly, the N-terminal
" portion ofthe proteins is the most conserved. There"are31 residues that are completely
conserved and 19 residues that are semi-conserved/ammig the proteins analyzed. The
conserved G-D-D-D residues,known to make up the catalytic signature of the X
polymerase enzymes, are among the completely conserved regions (Martin and Keller - ------
1996, Ylie et alI996). Based on sequence homology,to E. "coli CCA-adding enzyme'
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{""~"""'"" .. P. aeruginosa
Cca E. coli
B. Sllblilis
S. pnellllloniae
"Pap" { H. inflllenzaeE. coli
P. aerllginosa
{ ";"ff""w,
" " P. aerllginosa
Cca E. coli
B. sliblilis
S. pnellllloniae
"
{ H. inflllenzae
"Pap E. coli
P. aeruginosa
C'"'{
H. infillenzae
P. aerllginosa
E. coli
B. sliblilis
S. pnellllloniae
{ H. inflllenzae"Pap" E. coliP. aeTuginosa
Figure 7: Protein sequence alignment of the eTA-adding enzyme ("Cca") and Poly(A) polymel"3se I ("Pap") homologues of
represellliative Gram positive and Gram negative bacteria. The colored boxes highlight conserved residues among the nucleotidyltransferase
family (pink), poly (A) polymerases (orange), CCA-adding enzymes (green), or specific to the Gram positive bacteria (blue). The dashes
represent gaps in the alignment. The asterisk (*) denotes residw:ls in the G-D-D-D catalytic signature.
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Protein Sequence sources: H. inflllenzae Rd Cca, AAC23250; H. influenzae Rd PcnB, P44439; E. coli Cca, AAC76092; E. coli
PncB, P13685; B. subtilis PapS, P42977; P. aeruginosa PAOI Cca (gene #768) and Pap (gene #6159) from sequences generated
from University of Washington and Pathogenesis Corporation and annotated at University of Queensland webpage
(www.bit.uq.edu.au/pseudomonas); S. pneumoniae R6 Cca translated from polynucleotide sequence in Incyte proprietary database.
Figure 7 (continued): Protein sequence alignment of the CCA-adding enzyme ("Cca") and Poty(A) polymerase I ("Pap") homotogues of
representative Gram positive and Gram negative bacteria. The colored boxes conserved residues among the nucleotidyltransferase family (pink),
poly (A) polymerases (orange), CCA-adding enzymes (green), and specific to the Gram positive bacteria (blue). The dashes represent gaps in the
alignment. The asterisk (*) denotes residues in the G-D-D-D catalytic signature.
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versus E. coli poly(A) poly~~rase, the S. pneumoniae Cca sequence appears to be closer
to the poly(A) polyIp.erases than the CCA-adding enzymes (26 and 13 identical residues,
r
~;~~lurr~~~"'fesp~frWfyf'Howeve'r'B~-',$libtffifPap=S'7hMm{3i5Fmlll"grtm~1fumologr~§'liScS':2P<':=~~CLm'
pneumoniae Cca to the E. coli proteins and has been shown to function as a CCA-adding
,
enzyme (Raynal et alI998). Also, the Bacillus .and Streptococcus proteins have shared
homologi~ not found in the CCA-adding enzymes or poly(A) polymerases of the Gram
negative bacteria included in this analysis. From the protein sequence alignment, a clear
designation of the S. pneumoniae Cca protein as a CtA-adding enzyme is not possible,
though the similarity to the B. subtilis protein is highly significant (109 conserved
residues).
The operon structure for the S. pneumoniae cca gene and surrounding genes is not
very straightforward. Upstream isa gene homologous to Bacillus subtilis dapB which
/
encodes dihydrodipicolinate reductase, an enzyme.involved in the synthesis of lysine in
bacteria (Figure 8). This enzyme is not essential for in vitro growth of S. pneumoniae (D.
Holmes, personal communication). There appears to be a putative promoter and Shine-
Dalgarno sequences for dapB transcripts; however, no convincing promoter sequences
between the dapB and cca genes w~re observed. The cca gene does appear to be
translationally coupled to the down stream gene, yfmR because there is overlap between
the stop codon of cca and a possible start codon for yfmR. A ribosome binding site for
yfmR can be identified.as well. A homology search indicates that yfmR is a putative ABC
transporter.
28
-'H'"...l-:l~'{,.;,U''';:;:~~~=
-··-:<:;f;::-"'~3'.r::':'
RBS
Figure 8: Operon structure of region around S. pneumoniae ceQ. The promoter upstream of
dapB appears to be for all three genes, including eea. Ribosome binding sequences (RBS) Wvidentified for dapB and yfmR.
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Figure 8: Operon structure of region around S. [Jllewllolliae cca. The promoter upstream of
dupE appears (0 be for all three genes. including CUI. Ribosome binding sequences (RBS) were
identified for dupB and yjinR.
"
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B. Overexpression arid Purification of S. pneumoniae eca .
... NatiyeS. pneumoniae Ccais predicted to be 45.1 kDabased on the deduced
=az~~~·~~~;J1itfunu"a-eid;selIueniBe~",wmle'1His4ags;;~~-,N.rJmdc&\'t~rm!!l~~~1 R~~L~~J,gJU;;p:;:(;;;::.c.a~'!~~,.,,;
kDa and 46.2 kDa, respectively. These values corresponded well with the molecular
weights observed by SDS-PAGE. Small scale studies at 37°C showed the vast majority
of the S. pneumoniae Cca protein to be insoluble in all the E.coli expression hosts
screened (Figure 9, lanes 5, 9, 13, 19,23). Reducing the amount of protein produced by
lowering the temperature (18°C) and the amount of inducer did not improve solubility of
the protein. Moreover, attempts to solubilize the protein using alternative pH and salt
concentrations were unsuccessful.
~r-----------------------------------.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
kDa
43
29
Figure 9: S. pneumoniae Cca overexpression in E. coli at 31'C in the presence of 1 mM IPTG.
Lane 1: protein size marker; 2-5: BL21(DE3)/pJAOI (C-termini tagged) uninduced total cell lysate,
induced total cell pellet, soluble fraction, insoluble fraction; 6-9: BL21(DE3)/pJA03 (untagged)
uninduced total cell lysate, induced total cell pellet, soluble fraction, insoluble fraction; 10-13:
BL21(DE3)/pLysS+pJAOI (C-termini tagged) uninduced total cell lysate, induced total cell pellet,
soluble fraction, insoluble fraction; 14: protein size marker; 15: protein size marker; 16-19:
BL21(DE3)/pLysS+pJA02 (N-termini tagged) ullinduced total cell lysate, induced total cell pellet,
soluble fraction, insoluble fraction; 20-23: BL21(DE3)1pLysS+pJA03 uninduced total cell lysate,
induced total cell pellet, soluble fraction, insoluble fraction. Similar results were seen in all the other
hosts that p~oduced untagged or tagged S. pneumoniae Cca.
L..- --'. "".
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. However, it is conceivable ~hat any S. pneumoniae Cca protein in the soluble
fractions, even at if present in very low'amounts, could be purified directly from the E.
. ,'. • '. " . . '_ "~zc~;:;:"·~··:;",,,,.''''l£iif;};:';>4Jid!''C''"'i4~
gw<:.;'~~,~~);":;~~J1J~i~~~j~Jlimc~l~,"€Ok1111IW'!¥l1e"CIm'~d~nrc1&iidh~(·(&+)·i~the. .' . . .
column matrix selectively retain proteins with exposed histidine residues u!1til disrupted'
by high concentrations of imidazole salt. A western blot analysis was used to identify if
there was any soluble His-tagged S. pneumoniae Cca protein present in the celllysates.
Initial attempts focused on the N-terminally His-tagged construct because the His-tag
could be easily removed via thrombin cleavage if enzymatic activity was lacking due to
incorrect folding.
The western blot verified the presence of a small amount ofN-terminal His6 S.
pneumoniae Cca (Sp His6-Cca) in the soluble fraction and that it could be captured over
a Ni-affinity purification column (Figure lOB, Lanes 12 and i3). The majority of the Sp
His6-Cca was insoluble (Figure lOA and B, lanes 6 and 8). No His-tagged protein was
detected in the vector-only strain or the uninduced overexpressing straIn (Figure lOB,
lanes 1-5).
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Figure 10: Confirmation of His-tagged proteiI,lin soluble fraction of B~1(1)E3)/pJA02: A) SDS
PAGE, Coomassie stained. Lane 1: uninduced vector-only strain total protein, 2: induced vector-only
strain total protein, 3: uninduced BL21(DE3)/pJA02 total protein, 4: uninduced BL21(DE3)/pJA02
soluble fraction, 5: uninduced BL21(DE3)/pJA02 insoluble fraction, 6: induced BL21(DE3)/pJA02
total protein, 7: induced BL21(DE3)/pJA02 soluble fraction, 8: induced BL21(DE3)/pJA02 insoluble
fraction, 9: flow through fraction from soluble BL21(DE3)/pJA02 over Ni-affinity column, 10: 10 mM
imidazole wash fraction 1, 11: 10 mM imidazole wash fraction 6, 12: 500 mM imidazole elution
fraction 1, 13: 500 mM imidazole elution fraction 2, 14: 500 mM imidazole elution fraction 3, 15:
protein MW marker.' B) Western Blot; same samples as A, except 1I20th sample concentration
transferred to PVOF membrane and probed with alkaline phosphtase conjugated to Ni and detected
using ECF.
.From.the protein gel analysis of the Sp His6-Cca capture of the Ni-affinity column, it
was evident that some E; coli proteins co-eluted with the target protein (Figure IDA, lanes
12-14). To improve the purity o~the final elution, the wash steps were extend~d to
include a 100 roM imidazole wash step. The result was soluble Sp His6-Cca at about
90% purity (Figure 11). Protein in Fraction 2 from the 500 roM imidazole elution was
used in the subsequent protein activity assays along with the corresponding controls.
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Figure 11: Column purification of Sp His6·Cca from BL21(DE3)/pJA02 cell lysate: Lane 1:
protein marker, Lane 2: soluble fraction, Lane 3: flow through, Lane 4: 10 mM imidazole wash,
Lanes 5-10: 100 mM imidazole fractions 1,2,3,4,5; Lane 11: protein markers, Lanes 12-16: 500
mM imidazole fractions 1,2,3,4,5..
The presence of E. coli proteins in the purified fractions is controlled for in the
enzymatic assays by purified extracts of the vector-only strain, BL21(DE3)/pET28a,
under the same conditions (Figure 12). As a control for possible loss of activity due to
the purification scheme, the soluble fraction of the induced overexpressing strain was
incl~dt in the activity assays. The negative control fnr this sample was the vector-only
/olUble fraction (Figure 12).. Previous work with the Bacillus CCA-adding enzyme
overexpressed in E. coli (Raynal et al1998) showed that the CCA-adding enzyme and.
poly(A) polymerase assay conditions were sensitive enough to pick up activity from the
Bacillus protein in the soluble fractions without further purification, so it was anticipated
that·S. pneu1?loniae Cca activity' co~ld be detected in the solubl~ fractions as well. E. coli
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poly(A) polymerase I was used as a positive control because it has been demonstrated to
,"" ..". be active under both PAP and CCA-adding enzyme assay conditions and gives results
~r.-:tW..~;i-,~:itS~',·~~<;(~+~;~~}lJ.e;'~~~"!4U;zw~;r~.2i"~-;t~~~tn.m~~~r~~~~~~~,i~~.#7,~-f.t7~~~_L-fi?,;~~rfl:l.,~~;'~:bU"'--:l~~
distinguishable from a CCA:adding enzyme (Raynal et al1998).
1 2 3 4 5 6. 7
Figure 12: Protein gel of assay samples and controls.
Lane 1: protein size marker
Lane 2: purifiecLSp His6-Cca (from BL21(DE3)/pJA02)
Lane 3: 500 mM imfdazole"fiactioii-2 from
BL21(DE3)/pET28a)
. Lane 4: soluble fraction of BL21(DE3)/pJA02
Lane 5: soluble fraction of BL21(DE3)/pET28a
Lane 6: total protein sample from BL21(DE3)/pJA02
Lane 7: total protein sample from BL21(DE3)/pET28a
c. tRNA Nucleotidyltransferase Activity Assay
Use of a gel-based assay allowed clear differentiation between an enzyme that
adds one ot two labeled nucleotides (as would be anticipated from a CCA-adding
enzyme) from one adding multiple nucleotides (as in the case of poly A tailing by a
poly(A) polymerase). In Figure 13, the purified Sp His6-Cca protein (lanes 6, 9, 16)
incorporates both ATP and CTP into tRNA. Since yeast tRNAs range in size from 7S to
9S bases, the addition 'of one or two bases does not change the size sufficiently such that
the mobility of the tRNAs is not altered on the acrylamide gels. The tRNAs labeled by
the Sp His6-Cca appear as a single band around 77-97 b~es (Figure 13, lane 9 compared
to markers). This result is different from that observed·with the E. coli Poly(A)
polymerase (PAP). E. coli PAP· (lanes 4 and lO)"incorporates multiple ATP molecules,
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creating poly(A) tails at the 3' end of the tRNA molecules such that the resulting tRNA
ll$\'l\:;;'~~;';;:"'~;V:ii,;m.-"";:r.:tmQ~le£Jlr.e.QMtbgr.,;"ateItb~ 100 bases. E. coli PAP is unable to efficiently
, . .~.,. . a".rw.~"t."itt.."0:.M;m:,*~~~d".i'>~~J!.i~~='lirfrZl,~rr.';"""'WY4i:w.;;}i!';r:h"'tI{;¢~;:;'<_~~~~~.., '7';;"~~,:_
incorporate CTP (lane 14) while the purified Sp His6-Cca utilizes CTP (lane 16) with the
same efficiency as it does ATP (lane 6). There is no tRNA nucleotid~ltransferase activity
in the vector-only.control sample that was in.duced and purified in the same manner as the
purified Sp His6-Cca overexpres~ng strain. (lane 7 compared to lane 9).
Nucleotidyltransferase activity was detected in the soluble fraction of the Sp
His6-Cca overexpressing strain (Figure 13, lanes 2 and 12). Surprisingly, tRNA
nucle()tidyltransferase activity was detected in the soluble, fraction of the vector-only
control strain. Enzymatic activity from the vector-only strain fraction was not expected
because it was believed that the native E. coli CCA-adding enzyme was present at an
. undetectable concentration. However, an equivalent amount of the soluble fraction from
the strain overexpressitig Sp His6-Cca (Figure 13, lanes 2 and 12) yielded greater tRNA
---
nucleotidyltransferase activity than the vector-only control. .This increase in activity is
believed to be due to the presence of the Sp His6-Cca protein in the overexpressing
strain. Some background PAP activity also appears to be present in the soluble fractions
of the vector-only strain and Sp His6-Cca overexpressing strain (lanes 1-and 2) that is not
detected in the purified fractions. The PAP activity is presumably due to native E. coli
PAP and is fairly equal between the overexpressing strain and the vector-only control.
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Figure 13: tRNA nucleotidyltransferase assay results. To the left are results with labeled ATP
and to the right are results with labeled CTP. Lane 1: soluble protein fraction for vector-only strain
(4.28 ug total protein), Lane 2: soluble protein fraction for induced Sp His6-Cca overexpressing
strain (4.28 ug total), Lane 3: no protein, Lane 4: E. coli Pap, Lane 5: blank, Lane 6: 65 ng Sp
His6-Cca, Lane 7: purified fraction of vector only strain, Lane 8: soluble fraction for vector only
control (10.7 ug), Lane 9: 65 ng of Sp His6-Cca, Lane 10: E. coli Pap, M: size marker (133 bases
and 44 bases), Lane 11: soluble protein fraction for vector"only strain (4.28 ug), Lane 12: soluble
protein fraction for induced Sp His6-Cca overexpressing strain (4.28 ug), Lane 13: no protein, Lane
14: E. coli Pap, Lane 15: blank, Lane 16: 65 ng Sp His6-Cca.
D. Poly(A) Polymerase Activity Assay.
The results of the Poly(A) polymerase activity assay confirm what was observed
in the tRNA nucleotidyltransferase assay. It is a gel-based assay and similar to the tRNA
nucleotidyltransferase assay because of its ability to differentiate products of apoly(A)
polymerase and CCA-adding enzyme based on size. Under the PAP assay conditions,
,)
purified Sp His6-Cca appears to incorporate a very limited number of ATP molecules on
the 3' end of the tRNA molecules, presumably one since the tRNAs maintain sizes of 75-
95 bases (Figure 14, lanes 1,2,11). The E. coli PAP yields. a broad smear (lanes 3, 4,6)
indicative of numerous ATP added to the 3' end of the substrate. While tRNA is not the
native substrate of E. coli PAP, the enzyme will recognize the single-stranded tRNA. In
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fact, it has been shown that E. coli PAP has a repair function of adding cleaved adenosine
. 1997). However, there is known heterogeneity in the length of the poly(A) tail and under
these optimized condition for the polymerizing-activity Of PAP, the broad range in tRNA .
size after the addition of ATP was anticipated. The vector-only purified fraction did not
show any specific activity under PAP conditions (lane 10)..The soluble fraction of the Sp
His6-Cca overexpressing strain yielded results similar to purified Sp His6-Cca,
incorporating a limitied number ofATP molecules (lane 8): The vector,..only soluble
fraction did not show any nucleotidyltransferase or PAP activity under PAP conditions.
Figure 14: Poly(A) polymerase assay results. Left are results with labeled ATP and to the
right are additional results from a second experiment. Lane 1: 160 ng Sp His6-Cca, Lane 2:
65 ng Sp His6-Cca Lane 3: 3 units E. coli Pap, Lane 4: 1.5 units E. coli Pap, Lane 5: no
protein, Lane 6: 1 unit E. coli PAP, Lane 7: vector only soluble fraction (4.28 ug), Lane 8:
soluble fraction from Sp His6-Cca overexpression strain (4.28 ug), Lane 9: marker (44 bases),
Lane 10: vector only purified fraction, Lane 11: 65 ng purified Sp His6-Cca, Lane 12: marker
(44 bases).
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The results of the tRNA nucleotidyltransferase assay and the poly(A) polymerase
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-Discussion
pneumoniae Cca amino acid sequence indicated that S. pneumoniae Cca was a member of
the nucleotidyltransferase superfamily of enzymes. The family is defined by the
conserved residues in the catalytic domain, which consequently. make it difficult to
distinguishbetween'CGA-adding enzymes and poly(A) polymerase. Such ambiguity is·-'-:
typified by the example ofthe recently characterized Bacillus subtilis PapS protein.
Raynal et al (1998) showed the function of the protein to be a CCA-adding enzyme
despite the suggestions that the protein was similar to E. coli poly(A) polymerase 1. The
. .j
discrepancy between the gene name and protein function for B. subtilis PapS
\
demonstrates the dangers of bioinformatic-based annotation. Once an erroneous gene
annotation has occurred, the error can be repeated as subsequent researchers base their
assumptions on gene homology searches. Interestingly, the Bacillus protein had the
highest homology to the Streptococcus pneumoniae protein described, leading to the
hypothesis that the S. pneumoniae protein was. a CCA-adding enzyme.
The S. pneumoniae protein was cloned, His-tagged, overexpressed in E. coli, and
purified using affinity column chromatography. The enzyme was subsequently shown to
incorporate "33p_ATP and 33p_CTP into tRNA. Theincorporation of both nucleotides
appears to follow the addition of 1-2 CTP and a single ATP, characteristic ofCCA-
adding enzymes. The activity of the enzyme was easily distinguishable from poly(A)
polymerase-activity where-multiple ATP were incorporated-and CTEwas.not utilized
with the same efficiency. Cca proteins (Ii coli Cca, Bacillus subtilis PapS, and
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Sulfolobus shibatae Cc~) were found to be soluble in E. coli expression systems similar
&?~~~~~1't511iO~~~Muay~1i&-\VevFt;lne1ft'ajUritTOff~erex.pressed:SiI;pneU1ffi!fn iaer~~~,,,,,='>;;t~;;;~~
protein was insoluble. Attempts to solubilize the protein by changing conditions of the
lysis buffer w'ere not successful arid although it was considered, denaturation and re-
naturation of the protein was deemed a last resort because of the likely effects on the
activity of the protein. Instead, affinity column purification was employed to rescue any
soluble prote~n'present'and sufficient quantities of the S. pneumoniae protein in the N-
terminally His-tagged form to perform activity assays. In general, protein tags have
made it relatively easy to select proteins of interest from contaminating proteins.
Occasionally the tags may interfere with protein folding or become buried in the protein
via intramolecular interactions, but in this particular case, tagging the protein of interest
was a rapid and specific purification tool that was key to the success of the study.
The sensitivity of the tRNA nucleotidyltransferase activity assay was surprisingly
'"high for E. coli Cca. The native level of CCA-adding enzyme in the soluble fractions
was detectable (Figure 13, lanes land 11). This was the result of the very small amount
of soluble S. pneumoniae protein present in the overexpressing strain. Consequently,
large ~ounts of the crude extract had to concentrated, increasing the risk of
contamination with E. coli proteins. It should be noted that the tRNA
nucleotidyltransferase ,assay conditions were developed for E. coli and Bacillus proteins
(Raynal et al1998) and may not be optimized for the S. pneumoniae CCA protein in
terms of pH and salt concentration; However, the-ability to discem-the-activity-of-the-S.-
pneumoniae Cca from that of th~.Jlative E. coli protein can be seen with the purified
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samples, where no enzymatic activity was detected in the vector-only control (Figure 13,
Now that the function of the Streptococcus pneumoniae Cca protein has been
elucidated, it is important to consider whether this protein is a feasible antimicrobial
target. This protein would be considered a novel target because none of the current
antibiotics target the CCA-adding enzyme or other members of the nucleotidyltransferase
superfamily. A protein sequence comparison of several bacterial genomes indicates that
many bacteria have a CCA-adding enzyme (Figure 2). CI~arly, those bacteria that do hot
have the CCA sequence in the tRNA genes would be susceptible to inhibition of the
CCA-adding enzyme by an antimicrobial chemical. Whether cca is essential in the
bacteria with complete tRNA genes remains to be seen. The many large bacterial
genome sequencing projects may shed more light on the distribution of the CCA signal
within tRNA genes across bacterial strains of clinical interest and thus, the essentiality of
the enzyme in a broad spectrum of bacteria. While the enzyme is essential "in S.
pneumoniae, it would be important to know whether the enzyme is expressed in vivo
during an infection, though it is difficult to see how it could be silent.
Another consideration is the conservation of the active site within the
nucleotidyltransferase superfamily between prokaryotic and eukaryotic family members.
The ability of an antimicrobial agent to distinguish the bacterial CCA-adding enzyme
from a human homolog would be critical because the CCA signal is rarely encoded in
eUkaryotict~A genes;hence,theGGA-adding~enzyme-must bean essential~partofthe -
translational machinery in ,eukaryotes. There is little overall sequence similarity; the
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regions outside the G-D-D-D signature of the X polymerase superfamily are different
~,;-zA'='~m:t+'~'ft"b6t~t~tneljattert~lin'(fe1rf{aryoftce'81;yrni§;;tyij,&'ei7H"'99'6f-='Tlterefore;nInllr'Mtor!'~'~':'?*~)I";,":Hh-i;:",">Ja'" .
interactions mightbe possible that are specific tb prokaryotes by blocking the active site
or changing the configuration of the enzyme. A human homolog has not been identified
and crystal structure of a bacterial CCA-adding enzyme has not been completed.
--~---_. --- ~~-~--~--
However, there are well-charact~rizedmembers of the pr,oteiilfamily, sucn as DNA
polymerase ~, that may offer insight into how an inhibitor is interacting with conserved
portions of the enzyme.
The biochemical assay for CCA-adding activity appears to be amenable to high
throughput screening. The assay would monitor the addition of CTP and/or ATP onto the
3' end of damaged or incomplete tRNA. It is necessary for. the assay to be in a high-
throughput format (Le. amenable to 96 or 384 well microtiter plates) to screen a large
number of potential inhibitors. Using labeled nucleotides, as in this study, it would be
possible to monitor the CCA-adding enzyme activity, though the gel-based format used
in this study is not compatible for a high-throughput format. Instead, a way to capture the
substrate (tRNA) and measure the incorporation of the labeled nucleotides would be
favored. To determine the effect of an inhibitor, the assay must be robust and have a high
signal-to-noise ratio. The signal could be increased by: 1) having only damaged tRNA as
a substrate or a synthetic oligonucleotide without the CCA sequence, 2) using both
labeled ATP and CTP, and 3) using a label. that does not significantly interfere with the
enzymatic activity...
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In summary, the study has definitively demonstrated that the biochemical function
. \',,'
a.T~,l:··~::--~~~~7~-C"""-.l~.~·~~-c.-. _,~~- .. _ , . "" '.-:', _. " __ .', ",_~'~'''''' .,,~, _, _ _ ' . ' ',' ~
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molecules; it does not function as apoly(A) polymerase. Accordingly, a high-
throughput assay can be now designed to identify inhibitors of Cca which could be the
precursors to a new antimicrobial agent.
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